Recurrent ulcer after treatment with cimetidine or sucralfate

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Medicine

Background:

• Peptic ulcer disease (PUD) management requires understanding long-term recurrence after initial treatment.
• Cimetidine and sucralfate are common PUD treatments, but their long-term efficacy in preventing recurrence needs evaluation.

Purpose of the Study:

• To compare the 1-year recurrence rates of peptic ulcer disease after successful treatment with cimetidine versus sucralfate.
• To investigate the influence of factors like smoking on ulcer recurrence in patients treated with cimetidine or sucralfate.

Main Methods:

• A double-blind, 1-year follow-up study involving 143 patients treated with cimetidine and 115 with sucralfate.
• Endoscopic evaluation was performed upon symptom recurrence and at 2-4 and 9-11 months post-healing.
• No anti-ulcer medication was allowed during the follow-up period.

Main Results:

• Overall 1-year recurrence rates were high and similar between groups: 71% for cimetidine and 68% for sucralfate (p > 0.3).
• Asymptomatic ulcer relapse rates were also comparable: 26% for cimetidine and 23% for sucralfate (p > 0.4).
• Smokers showed significantly higher recurrence rates than non-smokers in the cimetidine group (83% vs 58%, p < 0.01) and a trend in the sucralfate group (76% vs 57%, p = 0.057).

Conclusions:

• Cimetidine and sucralfate demonstrate similar long-term effectiveness in preventing peptic ulcer disease recurrence.
• Smoking is a significant risk factor for ulcer recurrence, particularly in patients treated with cimetidine.
• The findings highlight the need for smoking cessation strategies in PUD management to improve long-term outcomes.